Literature DB >> 2584936

Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis.

R G Titus1, B Sherry, A Cerami.   

Abstract

The ability of mice to resist infection with L. major correlated directly with the capacity of their LNC to produce TNF in response to in vitro parasite challenge. Blocking TNF in vivo by passively administering anti-TNF antibodies exacerbated the course of L. major infection, resulting in substantially larger cutaneous lesions and elevated numbers of parasites within those lesions. In addition, treatment of infected mice with exogenous rHuTNF afforded host protection as evidenced by smaller lesion size and decreased parasite counts. Taken together, these results suggest a central role for TNF in resistance to L. major.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584936      PMCID: PMC2189541          DOI: 10.1084/jem.170.6.2097

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice.

Authors:  R G Titus; R Ceredig; J C Cerottini; J A Louis
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

Review 3.  Immunological regulation and control of experimental leishmaniasis.

Authors:  J G Howard
Journal:  Int Rev Exp Pathol       Date:  1986

4.  Identification of an infective stage of Leishmania promastigotes.

Authors:  D L Sacks; P V Perkins
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

5.  Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.

Authors:  L M Green; J L Reade; C F Ware
Journal:  J Immunol Methods       Date:  1984-05-25       Impact factor: 2.303

6.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

7.  Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models.

Authors:  B A Sherry; J Gelin; Y Fong; M Marano; H Wei; A Cerami; S F Lowry; K G Lundholm; L L Moldawer
Journal:  FASEB J       Date:  1989-06       Impact factor: 5.191

8.  Higher frequency of Leishmania major-specific L3T4+ T cells in susceptible BALB/c as compared with resistant CBA mice.

Authors:  G Milon; R G Titus; J C Cerottini; G Marchal; J A Louis
Journal:  J Immunol       Date:  1986-02-15       Impact factor: 5.422

9.  A limiting dilution assay for quantifying Leishmania major in tissues of infected mice.

Authors:  R G Titus; M Marchand; T Boon; J A Louis
Journal:  Parasite Immunol       Date:  1985-09       Impact factor: 2.280

10.  Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae.

Authors:  D S Silberstein; J R David
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

View more
  70 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

2.  Deficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malaria.

Authors:  H Sam; Z Su; M M Stevenson
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

4.  Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route.

Authors:  C A Power; G Wei; P A Bretscher
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

5.  Association of a functional TNF variant with Plasmodium falciparum parasitaemia in a congolese population.

Authors:  T N Nguyen; S Baaklini; F Koukouikila-Koussounda; M Ndounga; M Torres; L Pradel; F Ntoumi; P Rihet
Journal:  Genes Immun       Date:  2017-07-13       Impact factor: 2.676

6.  Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.

Authors:  T M Scharton; P Scott
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

7.  Characterization of the immunogenetic basis of ultraviolet-B light effects on contact hypersensitivity induction.

Authors:  I Kurimoto; J W Streilein
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

8.  Lutzomyia longipalpis salivary gland homogenate impairs cytokine production and costimulatory molecule expression on human monocytes and dendritic cells.

Authors:  Dirceu J Costa; Cecília Favali; Jorge Clarêncio; Lílian Afonso; Viviane Conceição; José Carlos Miranda; Richard G Titus; Jesus Valenzuela; Manoel Barral-Netto; Aldina Barral; Cláudia Ida Brodskyn
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans.

Authors:  Y A Skeiky; D R Benson; J A Guderian; J A Whittle; O Bacelar; E M Carvalho; S G Reed
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  Interleukin-4 but not gamma interferon production correlates with the severity of murine cutaneous leishmaniasis.

Authors:  L Morris; A B Troutt; K S McLeod; A Kelso; E Handman; T Aebischer
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.